AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 292 min read$EXEL

Two medicines generated $605 million in U.S. sales for Exelixis in one quarter.

Exelixis reported Q3 2026 revenues of $605M, driven by its cabozantinib franchise. The company also highlighted progress in its zanzalintinib development program, with ongoing trials and expected topline results in Q1 2027. Exelixis updated its 2026 financial guidance, reflecting these developments.

Original reporting
stocktitan.net
Published Oct 29, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$EXEL
Bullish
high confidence
Mentioned
$EXEL
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$EXELBullishHigh
01

Why it matters

The earnings release introduces fresh revenue and guidance numbers, setting a new baseline for valuation and influencing biotech sentiment.

02

Market read

Exelixis' quarterly results and guidance are primary drivers for the stock and may affect related oncology biotech peers.

03

What to watch

Upcoming Phase 3 trial data for zanzalintinib could offset short‑term earnings disappointment.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Exelixis highlighted its cabozantinib franchise, announced progress on zanzalintinib trials, and provided FY2026 guidance.

Company-level read

Ticker impact

$EXELBullishHigh confidence
Context

Exelixis reported Q3 2026 results and updated FY2026 guidance, including $605 M U.S. sales from two medicines.

Expected impact

potential downside as guidance may fall short of expectations

Evidence & confidence

New financial numbers and guidance can move the stock immediately; investors will reassess valuation.

Market effects

Sector

Biotech sector may react to Exelixis' guidance and trial updates.

Regional

U.S. biotech investors will adjust exposure based on the results.

Global

Limited to investors tracking oncology drug pipelines.

Counterpoint

What could challenge this read

If guidance is perceived as weak, the stock could rebound on long‑term pipeline potential.

Key entities

  • company
    Exelixis Inc.

    U.S. biotech company developing oncology drugs.

  • partner
    Merck

    Collaborates with Exelixis on zanzalintinib trials.

Read at source← All news

StoryExelixis beats Q3 estimates and maintains 2026 revenue guidance

Also covered by

2 outlets

Related articles

OCT 29
$EXELMedAI 8/10

Exelixis beats Q3 estimates but stock edges lower on guidance

Exelixis (NASDAQ:EXEL) reported Q3 adjusted EPS of $0.94, beating estimates by $0.07, with revenues of $658.7M, up 10.2% YoY. FY2026 revenue guidance of $2.5B-$2.55B was maintained, slightly below analyst consensus. Shares fell 0.15% post-announcement. The company expects topline results from its phase 3 STELLAR-304 trial in Q1 2027 and updated its effective tax rate guidance to 16%-18%.

investing.com6 min
OCT 29
$EXELMedAI 8/10

Exelixis: Q3 Earnings Snapshot

Exelixis Inc. (EXEL) reported Q3 profit of $218.1M, or 85 cents per share, beating analyst estimates of 89 cents. Revenue was $658.7M, exceeding forecasts of $653.1M. The company expects full-year revenue of $2.5B to $2.55B.

finance.yahoo.com2 min
OCT 29
$EXELHighAI 8/10

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

EXELIXIS, INC. (EXEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces Third Quarter 2026 Financial Results and Provides Corp

SEC EDGAR 8-K2 min
OCT 14
$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

prnewswire.com3 min